GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » DOD Biotech PCL (BKK:DOD-R) » Definitions » Return-on-Tangible-Asset

DOD Biotech PCL (BKK:DOD-R) Return-on-Tangible-Asset : 9.48% (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is DOD Biotech PCL Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. DOD Biotech PCL's annualized Net Income for the quarter that ended in Mar. 2025 was ฿108.8 Mil. DOD Biotech PCL's average total tangible assets for the quarter that ended in Mar. 2025 was ฿1,148.0 Mil. Therefore, DOD Biotech PCL's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 9.48%.

The historical rank and industry rank for DOD Biotech PCL's Return-on-Tangible-Asset or its related term are showing as below:

BKK:DOD-R' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -27.41   Med: 7.49   Max: 54.65
Current: -11.02

During the past 11 years, DOD Biotech PCL's highest Return-on-Tangible-Asset was 54.65%. The lowest was -27.41%. And the median was 7.49%.

BKK:DOD-R's Return-on-Tangible-Asset is ranked worse than
89.07% of 1940 companies
in the Consumer Packaged Goods industry
Industry Median: 3.62 vs BKK:DOD-R: -11.02

DOD Biotech PCL Return-on-Tangible-Asset Historical Data

The historical data trend for DOD Biotech PCL's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DOD Biotech PCL Return-on-Tangible-Asset Chart

DOD Biotech PCL Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.87 2.96 -27.41 0.53 -12.03

DOD Biotech PCL Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 -54.28 2.53 1.38 9.48

Competitive Comparison of DOD Biotech PCL's Return-on-Tangible-Asset

For the Packaged Foods subindustry, DOD Biotech PCL's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DOD Biotech PCL's Return-on-Tangible-Asset Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where DOD Biotech PCL's Return-on-Tangible-Asset falls into.


;
;

DOD Biotech PCL Return-on-Tangible-Asset Calculation

DOD Biotech PCL's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-159.333/( (1406.91+1243)/ 2 )
=-159.333/1324.955
=-12.03 %

DOD Biotech PCL's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=108.816/( (1243+1053.065)/ 2 )
=108.816/1148.0325
=9.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


DOD Biotech PCL  (BKK:DOD-R) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


DOD Biotech PCL Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of DOD Biotech PCL's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


DOD Biotech PCL Business Description

Traded in Other Exchanges
Address
No. 111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The company is organized into business units based on its products and services and has reportable segments as; Supplementary business, Manufacturing cosmetic business, Manufacturing extraction business, and others. A majority of its revenue is generated from the Supplementary business which manufactures and sells dietary supplements in the form of capsules, tablets, soft gels, gummies, probiotics, shot drinks, and others. Geographically, the company operates only in Thailand.

DOD Biotech PCL Headlines

No Headlines